Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity

High Grade Osteosarcoma Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02273583
• Other study ID #: GLATO 2006
• Status: Recruiting
• Phase: Phase 2
• First received: July 7, 2014
• Last updated: February 10, 2016
• Start date: May 2006

Study information

• Verified date: February 2016
• Source: Grupo de Apoio ao Adolescente e a Crianca com Cancer
• Contact: Sérgio Antônio Petrilli, MD
• Phone: 55-11-5080-8494
• Email: sergiopetrilli[@]graacc.org.br
• Is FDA regulated: No
• Health authority: Brazil: National Ethics CommissionBrazil: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Preclinical models show that a daily antiangiogenic regimen at low-dose may be effective against chemotherapy-resistant tumors. The aim of this study is to evaluate the efficacy of maintenance therapy with continuous oral cyclophosphamide and methotrexate in patients with high grade, operable, non-metastatic osteosarcoma (OST) of the extremities. The primary end point is event-free survival (EFS) from randomization.

Description:

The study design includes a backbone of 10 weeks of preoperative therapy using MAP (High-dose methotrexate, cisplatin, and doxorubicin). Following surgery, non-metastatic patients were randomized by blocks to complete 31 weeks of MAP or to receive 73 weeks of maintenance therapy following MAP; while metastatic patients received maintenance therapy in combination with MAP since the beginning of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 738
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 30 Years

Eligibility

Inclusion Criteria:

1. Patients with high-grade malignancy osteosarcoma , biopsy-proven , newly diagnosed , previously untreated . Patients with osteosarcoma as a second malignancy should also be eligible .

2. Patients with any primary site , with or without metastases at diagnosis , will be accepted and treated.

3. Patients < 30 years.

4. Patients must have normal body function and adequate renal function defined as serum creatinine < 1.5 x the normal value or creatinine clearance > 60ml/min/1 ,73m2 .

5. Patients must have adequate hepatic function, defined as total bilirubin < 1.5 x normal, aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) < 2.5 x normal.

6. Patients must have adequate cardiac function defined by a shortening fraction > 27 % by echocardiogram or ejection fraction > 47 % by radioisotopic angiogram .

7. If pre- chemotherapy amputation is necessary, the patient is included in the study and eligible to survival analyzes, however the pathological analyze response will be not performed.

Obtain material for pathological and molecular study is recommended .

8. Whenever possible a central catheter should be placed against the intensity of chemotherapy and need for forced hydration .

9. Patient or legal guardian must sign a consent form which will be explain the type of treatment and procedures that the patient will be submitted .

10. Time > than 4 weeks between biopsy and initiation of treatment - Restaging

Exclusion Criteria:

1. Disease progression ( increase of at least 20% of the extent of the lesion, taking as reference the smallest measurement recorded from the start of treatment, or the appearance of one or more lesions );

2. Any properly documented clinical situation , which at the discretion of the attending physician , patient can not follow with chemotherapy , for safety reasons ;

3. The evaluation of cardiac aspects will be done carefully , so will exclude patients with 20% reduction in the ejection fraction of the left ventricle compared to baseline or with a ventricular ejection fraction < 45 % regardless of baseline;

4. The patient refusal to continue treatment ;

5. Nephrotoxicity , neurotoxicity and ototoxicity grade 4 ;

6. Delay greater than 40 days for the realization of the next treatment cycle , not related to toxicity;

7. Refusal of surgery ; 8 . Variation above 20% of the recommended dose without justification.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• High Grade Osteosarcoma
• Osteosarcoma

Intervention

Drug:
• continuous oral cyclophosphamide and methotrexate

Locations

Country	Name	City	State
Brazil	GRAACC- Institute of Pediatric Oncology	São Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
Grupo de Apoio ao Adolescente e a Crianca com Cancer

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-Free Survival	AT 5 YEARS	EFS AT 5 YEARS	No
Secondary	Overall survival	AT 5 YEARS	OS AT 5 YEARS	No